RxDoctor Payments DataLook up a doctor →

Kathleen Woschkolup, MD

Neurology · Greenville, SCNPI 1003013616

Payments from drug & device makers

$110,483in general payments, 2019–2025

Across 625 payments — averaging $176.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$76K
  • Neurocrine Biosciences, Inc.$22K
  • Acorda Therapeutics, Inc$5K
  • Teva Pharmaceuticals USA, Inc.$2K
  • AbbVie$1K
  • Biohaven Pharmaceuticals, Inc.$690
  • plus $4K from 44 others
$15,000in research payments, 2019–2025

Across 4 payments — averaging $3750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$15K

What the payments were for

  • Consulting fees$20,38021%
  • Speaking & faculty fees$64,04366%
  • Travel & lodging$3,0873%
  • Food & beverage$9,65310%
  • Education$3210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,483 in reported general payments places this provider in the 90th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$666,262
Medicare patients
401
Services billed
66,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate259$1,393,275
GocovriAmantadine Hcl100$417,938
RytaryCarbidopa/Levodopa182$304,183
IngrezzaValbenazine Tosylate12$91,554
BotoxOnabotulinumtoxina46$73,030
OngentysOpicapone44$40,869
Carbidopa-LevodopaCarbidopa/Levodopa795$39,596
Carbidopa-Levodopa ErCarbidopa/Levodopa614$29,876
RivastigmineRivastigmine Tartrate131$11,640
Droxidopa42$10,716
UbrelvyUbrogepant11$10,298
Rasagiline Mesylate40$8,631
Ropinirole Hcl169$6,943
Carbidopa16$6,739
AmantadineAmantadine Hcl124$5,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$76,300$1,393,275259 claims
MDD US Operations, LLCGocovri$434$417,938100 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$39$304,986194 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$21,814$132,42456 claims
AbbVieBotox, Ubrelvy$1,203$83,32857 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 270 neurology providers in South Carolina.

Other neurology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →